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Abstract
A 60-year-old male presented to the emergency department
(ED) with a 1–2 day history of confusion, headache, and subjective fever. Because he had met with a contact two days
prior to admission who had recently traveled from the Bahamas, a COVID-19 nasopharyngeal (NP) and oropharyngeal (OP) polymerase chain reaction (PCR) test was ordered.
He was diagnosed with bacterial meningitis based on presenting neurologic symptoms and the identification of Streptococcus pneumoniae from blood cultures. The COVID-19
NP and OP test returned positive, although he never devel-

oped shortness of breath, cough, other respiratory symptoms,
diarrhea, abdominal pain, nausea, vomiting, or any change
in sense of smell or taste. On day 3 of hospitalization, the
patient had improved clinically on intravenous (IV) antibiotics
and was discharged home with instructions to self-quarantine.
This case demonstrates the possibility of co-infections with
COVID-19 and raises the possibility of an association between COVID-19 and patient susceptibility to invasive pneumococcal disease (IPD).

Introduction

tient was in his baseline health the night prior to admission, which is alert and oriented times four. On the
morning of admission, she noted that the patient was
chilled and shaking, and asking for a blanket. At that
time, he stopped talking and was noted to be extremely
weak, unable to stand up without full assistance. She
denied any recent illness, cough, shortness of breath,
nausea, vomiting, or diarrhea. The patient’s wife did
report that the patient recently returned from a trip to
Spain. No specifics on the trip were included in the patient’s medical record (departure, return, duration, destinations, activities, etc.). The family also reported that
the patient had contact with a friend two days prior
to admission who had recently traveled from the Bahamas. The person who had traveled to the Bahamas
had been back in the United States for about two weeks
with no respiratory, gastrointestinal, or other infectious
symptoms. No other known sick contacts or possible
exposures were noted.

Previous literature has shown associations with both
influenza and respiratory syncytial virus activity
and the incidence of both IPD and pneumococcal
meningitis.[1-5] Currently, no such association or examples have been provided with COVID-19 and IPD.
With the rapid progression of COVID-19 prevalence
and mortality, the documentation and characterization
of potential complications and risks of COVID-19 are
needed. This case describes concomitant pneumococcal meningitis in a patient positive for COVID-19 and
discusses the potential role that COVID-19 may have
in the pathogenesis of IPD and meningitis.

Case Report
A 60-year-old male presented to emergency department with a one to two day history of confusion,
headache, and subjective fever. His past medical
history includes hypertension, hyperlipidemia, and
arthritis, and has no vaccination history listed in his
medical record. The patient’s wife described the pa-

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/42

Initial vital signs were significant for a temperature of
39.1 °C (102.3 °F) and heart rate of 104 bpm (Table
1). The physical exam in the ED noted no nuchal
rigidity and was unremarkable other than severely al-
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Table 1. Vital signs.

Hospital day
Initial
Day 1
Day 2
Day 3

Temperature
(°F)

Heart rate
(beats/min)

Respiratory rate
(breaths/min)

Blood pressure
(mm Hg)

102
97.5–102
96.7–98.4
97.6–98.3

115
84–115
76–110
68–75

22
16–26
13–26
16–17

177/108
150–191/81–109
113–157/70–96
134–153/85–91

Table 2. Laboratory values.

Hospital day
Day 1
Day 2
Day 3
(Day 7)
(Day 14)

WBC
103 cells/µL

Lymphocyte
%

T- Bili
mg/dL

ALT
U/L

AST
U/L

Alk phos
U/L

PCT
ng/mL

Lactic acid
mmol/L

CRP
mg/dL

ESR
mm/hr

15.55
23.74
22.59
9.26
6.62

4.9
2.7
3.3
15.2
16.5

1.1
–
–
–
–

31
–
–
–
–

44
–
–
–
–

61
–
–
–
–

–
6.34
–
–
–

3.8
6.3
–
–
–

–
–
–
2.5
1.5

–
–
–
31
34

Abbreviations: Alk phos, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP,
c-reactive protein; ESR, erythrocyte sedimentation rate; PCT, procalcitonin; WBC, white blood cell count.

tered mental status and non-verbal status. Brudzinski’s
or Kernig’s signs were not assessed. Significant labs
on admission included an elevated WBC of 15.55×103
cells/µL, elevated procalcitonin of 6.34 ng/mL, and an
elevated lactic acid of 3.8 mmol/L (Table 2).
Chest X-ray reported no evidence of cardiopulmonary
abnormality. A CT of the head, chest, abdomen and
pelvis was obtained. The head CT without contrast
demonstrated no mass lesion, hemorrhage or acute artifact. The chest CT without contrast was limited by
motion artifact, but did not show any evidence of acute
airspace disease or pleural effusion (Figure 1). Subsequently, an MRI of the brain with and without contrast
was obtained (Figures 2 and 3). The report noted fluid
with restricted diffusion layers dependently in the lateral ventricles without hydrocephalus consistent with
ventriculitis. The image was limited by motion to assess for corresponding enhancement or leptomeningeal
enhancement. Due to the noted travel history and contact, the patient was tested for COVID-19 disease by
a combined nasopharyngeal/oropharyngeal swab sent
for PCR and the patient was placed in appropriate
isolation. Unfortunately, a lumbar puncture was not
obtained due to COVID-19 isolation. Treatment was
started with ampicillin 2 g IV q4 hours, ceftriaxone 2 g
IV q12 hours, vancomycin 1,750 mg IV q12 hours, and
dexamethasone 10 mg IV q6 hours for suspected acute
bacterial meningitis.
The patient significantly improved with antibiotics.
Two of two blood culture sets resulted on day two of
admission with gram-positive cocci in pairs and chains.
Streptococcus pneumoniae was identified by the Verigene system (Nanosphere Inc., Northbrook, IL, USA).
Susceptibilities identified a multidrug resistant StrepULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/42

tococcus pneumoniae on day three of admission. The
S. pneumoniae MIC was 2 µg/mL to penicillin and 2
µg/mL to ceftriaxone. On the third day of admission, the SARS-CoV-2 PCR resulted positive. The
patient remained without evidence of symptoms related to COVID-19 disease (respiratory, gastrointestinal) throughout his hospital admission. The patient received IV vancomycin after discharge for the duration
of their meningitis therapy.

Discussion
The pathogenesis of pneumococcal meningitis consists of bacterial colonization of mucous membranes,
translocation into the bloodstream, survival in the
bloodstream, and eventual entry and replication in
the central nervous system.[6, 7] Before S. pneumoniae
can colonize, it first needs to adhere to mucosal surfaces, which it accomplishes through three different
types of receptors: the platelet-activating factor receptor, laminin receptors, and the polymeric immunoglobulin receptor. After initial adherence, colonization is
promoted by the evasion of secretory immune globulin A (IgA). Pathogen secretion of proteases helps to inactivate IgA. Although it widely varies from study to
study, S. pneumoniae colonization of the nasopharynx
is generally considered common even in healthy children and adults with its incidence reported anywhere
from 8.6% to 33.2%.[8, 9] After sufficient colonization of
the pathogen, invasion of tissues and translocation into
the bloodstream can occur. Although this occurs significantly less often than colonization, there are many
factors that can facilitate translocation into the bloodstream including environmental factors, host factors,
and pathogen virulence.
2
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Figure 1. Computed tomography image of the chest with no evidence or findings of cardiopulmonary abnormalities.
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Figure 2. Magnetic resonance image of the brain showing bilateral
6 mm x 4 mm collections layering in the posterior horns of the lateral
ventricles (red arrows). The differential diagnosis includes ventriculitis versus mild subarachnoid hemorrhage.

The association between respiratory viruses and increased incidence of IPD and pneumococcal meningitis has been documented, which is a common example of environmental factors influencing pneumococcal
disease.[10-13] Possible mechanisms of increased susceptibility to IPD include the respiratory viruses’ ability to impair the host’s innate immune system by recruiting inflammatory mediators and damaging mucosal and epithelial tissue.[11-14] Damage to these tissues and the resulting mucosal impairment and increased permeability of epithelia can facilitate bacterial pathogen adherence and promote translocation.
This has been commonly used to explain the association between both influenza and RSV activity and the
increased incidence of IPD and meningitis. Specific
mechanisms have been described, including a synergistic activation of interferons from influenza virus and
pneumococcal coinfection [12] as well as the stimulation of the platelet-activating factor receptor in the host
defense against S. pneumoniae following influenza infections.[13]
The primary route of entry for SARS-CoV-2 is thought
to be through the nasopharynx, which can eventually progress into the airways and lower respiratory
tract.[15] Similar to other viral pathogens, COVID-19
has been shown to recruit inflammatory cytokines including IL-1, IL-6, IL-7, IL-8, IL-9, IL-10, IFN-γ, and
TNF-α among others.[16, 17] These pro-inflammatory
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Figure 3. Brain MRI Gradient ECHO: Magnetic resonance image
with normal signal suggesting low likelihood for subarachnoid hemorrhage.

mediators that have been found in patients with
COVID-19 are also known to cause tissue damage, and
may provide a link to COVID-19 and increased host
susceptibility to IPD.
This case provides an example of a patient that was either colonized or infected with SARS-CoV-2, and that
developed concomitant pneumococcal meningitis. Interestingly, this patient did not demonstrate any signs
or symptoms consis- tent with pneumonia from either
S. pneumoniae or COVID-19. Although cause cannot
be determined, this case demonstrates the ability of
COVID-19 to co-habit with bacterial pathogens, and
raises the question of whether COVID-19 can be involved in the pathogenesis of and susceptibility to IPD
similar to what has been described with other respiratory viruses.
Another key point is the importance of epidemiology in
screening and diagnosis of patients during an outbreak
in addition to symptoms and radiographic evidence
of disease. This patient would likely not have been
screened without the mention of a possible sick contact
and travel history, which may have resulted in further
spread of COVID-19. Patients with known or high-risk
exposure during an outbreak (such as sick contacts or
travel history) should be tested for COVID-19 in order
to decrease spread from persons with asymptomatic
carriage or subclinical presentation.
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